<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85689">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01933750</url>
  </required_header>
  <id_info>
    <org_study_id>EU-001</org_study_id>
    <nct_id>NCT01933750</nct_id>
    <nct_alias>NCT01910207</nct_alias>
  </id_info>
  <brief_title>Trial of the PresView Implant for the Improvement of Near Vision in Presbyopic Patients</brief_title>
  <official_title>A Prospective, Multicenter, Controlled Clinical Study of the PresVIEW Scleral Implant for the Improvement of Near Visual Acuity in Presbyopic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Refocus Ocular Europe, B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Refocus Ocular Europe, B.V.</source>
  <oversight_info>
    <authority>United Kingdom:  National Health Service, Health Research Authority</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to determine the effectiveness of the PresVIEW Scleral Implant to improve near vision
      in patients who require reading glasses
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Near Visual Acuity</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of the distance Corrected Near Visual Acuity at 40 centimeters compared to baseline measurement.  A minimum of 75% of patients with a bilateral post-operative Distance Corrected Near Visual Acuity of .5 (20/40) or better at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Near Visual Acuity</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percent of patients with a bilateral post-operative uncorrected near visual acuity (UCNVA) at 40 centimeters of .5 (20/40) or better at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Significant Safety Events</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Several indicators of safety are monitored including but not limited to Best Corrected Distance Visual Acuity, Intra-ocular Pressure, and Chronic Inflammation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>Randomized/Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>7 patients randomized to deferred treatment/control cohort at the 3 sub-study control sites = 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Randomized/Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are non-randomized and if meet inclusion criteria receive the implantation of the PresVIEW device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PresVIEW Device Implantation</intervention_name>
    <arm_group_label>Non-Randomized/Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 45 or older at commencement of study

          -  Best Corrected Distance Visual Acuity of .80 (20/25) or better

          -  Patients must be alert, mentally competent, and able to comply with clinical study
             requirements

        Exclusion Criteria:

          -  Any previous eye surgeries including cataract, LASIK (laser in situ keratomileusis),
             or eye muscle surgery

          -  Any chronic systemic diseases such as diabetes, heart disease, Lupus, etc.

          -  Any eye diseases such as eye inflammation, infection, cataract, or retinal diseases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Selene Burke, O.D.</last_name>
    <phone>214-368-0200</phone>
    <email>sburke@refocus-group.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jason Schmitt, O.D.</last_name>
    <phone>214-368-0200</phone>
    <email>jschmitt@refocus-group.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique de la Vision</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dominique Pietrini, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Goethe - University Department of Ophthalmology</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thomas Kohnen, MD, PhD, FEBO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johannes-Gutenberg-Universitat</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Urs Bossmerbaumer, Dr. Med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Area Oftalmologica Avanzada</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Carlos Verges, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midland Eye</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sunil Shah, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 30, 2013</lastchanged_date>
  <firstreceived_date>August 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Presbyopia</keyword>
  <keyword>Reading Glasses</keyword>
  <keyword>Near Vision</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
